{"id":1337,"date":"2023-04-12T09:00:06","date_gmt":"2023-04-12T09:00:06","guid":{"rendered":"https:\/\/discovery-park.co.uk\/?p=1337"},"modified":"2023-08-29T13:48:34","modified_gmt":"2023-08-29T13:48:34","slug":"discovery-park-ventures-grows-portfolio-with-addition-of-two-new-investments","status":"publish","type":"post","link":"https:\/\/discovery-park.co.uk\/discovery-park-ventures-grows-portfolio-with-addition-of-two-new-investments\/","title":{"rendered":"Discovery Park Ventures Grows Portfolio with Addition of Two New Investments"},"content":{"rendered":"
Discovery Park Ventures<\/a>\u00a0(DPV), the early stage life\u00a0 sciences fund associated with Discovery Park, has made investments in two high-potential businesses,\u00a0Ignota Labs<\/a>\u00a0and\u00a0Oxford Medical Products<\/a>. The funding, which \u00a0takes the number of companies in its portfolio to six, makes a significant contribution to the growth trajectory of both firms as they work towards their next milestones. \u00a0Established in 2022, DPV invests in novel and disruptive technology usually related to\u00a0 Discovery Park\u2019s focus areas1\u00a0<\/sup>and has plans to expand to up to \u00a325m.<\/p>\n Ignota Labs is helping drug developers navigate the toxicity landscape of drug \u00a0discovery with state-of-the-art scalable toxicity screening tools for the pharma and biotech industry. It provides insights across a range of toxicity problems, enabling\u00a0 improved drug design optimisation from the start of the discovery process. The\u00a0 company believes that proactive use of its technology has the potential to save the \u00a0industry significant amounts of time and billions of pounds each year via reduced \u00a0failure risk and creation of improved drug candidates. Also backed by\u00a0Sustainable Ventures<\/a>,\u00a0 Ignota Labs has completed its first strategic partnership and is now raising a \u00a0\u00a31.5m seed round.<\/p>\n <\/p>\n Oxford Medical Products, led by CEO Dr\u00a0Camilla Easter<\/a>, has developed the novel weight-loss product Sirona. Excessive weight increases the risk of poor health and is estimated to cost the global economy over $2tn every year. Based on a proprietary\u00a0 hydrogel and now in clinical trials, Sirona comprises a self-expanding pill which \u00a0occupies physical space in the stomach, reducing hunger and leading to significant \u00a0weight loss in a non-invasive way. In addition to Discovery Park Ventures, Oxford \u00a0Medical Products is backed by Ada Ventures, Nesta VC, Selvedge Venture and OION.<\/p>\n